Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tomorrow is the day to get your...
....ticket to the show. They'll be on sale starting at 9:30AM EST and will increase in price until 4:30PM EST.
Monday Genta will broadcast to the world what they're doing as a groundbreaking drug company for hundreds of investors.
I'm very excited to kickback and watch it all go down. Gonna be fun to watch and I'm glad I've got front row seats!
Anyone who trades in the pinks needs to have their seat as well...tomorrow is your last chance at these prices.
GNTA hasn't had back to back red volume days since January 12th and has only had 2 pullback days out of the last 10...that trend will continue tomorrow in a big way.
Next leg up starts at 9:30AM...come along for the ride, folks.
Gonna be fun!
Several consecutive up days....
...followed by a slight pull-back day. That's healthy.
Do you folks remember when this first broke a penny? The following day, it dipped down after making that run. One day later it closed above .0126, then made a run all the way up to .0175. There has to be some pull back.
Don't get scared because the stock isn't picking up 40% gains every single day, that's just not reality. It's trading very healthily and looks fantastic running into tomorrow.
If you sell now, you have serious problems and lack experience. Watch for the dip in the morning (like it ALWAYS does), then grab the horns.
The Bull is leaving the station.
People realizing they have to get in now or chase later...
...this is going to climb right in to tomorrow's close.
You'd be crazy not to have a position here before Monday.
She's about to move up nicely here
This happens every day just before we make a new HOD.
Newbies get shook, vets get paid.
We are all excited about Genasense potential, but has anyone really discussed the potential of Tesetaxel? Good lord! This could actually be even bigger than Genasense.
Tesetaxel is a novel oral semi-synthetic taxane. Taxanes, such as paclitaxel (Taxol®) and docetaxel (Taxotere®), are mainstays of modern anticancer therapy. These drugs are believed to kill cancer cells by disrupting critical cellular proteins. Taxanes have been formally approved by FDA for the treatment of breast, lung, ovarian, gastric, and prostate cancers. However, all currently approved taxanes require intravenous (IV) infusion under close medical supervision. Moreover, both paclitaxel and docetaxel can cause severe, occasionally fatal, infusion reactions, which require pre-medication with steroids and antihistamines. Other serious reactions associated with taxanes include long-lasting damage to peripheral nerves (neuropathy). An oral taxane with the anticancer activity of the IV drugs could provide substantially greater patient safety (by eliminating infusion reactions and precluding the need for pre-medication), a high level of patient convenience, and potentially greater flexibility to explore novel dosing schedules that might improve overall outcomes for patients.
In preclinical testing, tesetaxel has shown clear anticancer activity, including activity against cancer cells that were resistant to paclitaxel and docetaxel. Typically, cancer cells become resistant to taxanes by a mechanism known as “multidrug resistance” that is mediated by a factor called p-glycoprotein. Resistance to tesetaxel did not appear to be mediated by this mechanism, suggesting that tesetaxel might be useful for diseases that are resistant to conventional taxanes.
Genta Incorporated (OTCBB: GNTA.OB) announced it has initiated a new clinicaltrial with tesetaxel, the latest addition to Genta`s oncology product portfolio.Unlike standard taxanes such as paclitaxel (Taxol®), which must be infused intravenously, tesetaxel is administered by mouth as a capsule. The new study will examine the clinical pharmacology of the drug over a narrow dosing rangearound the established Phase 2 dose. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.
"Taxanes are the most widely used class of anticancer compounds," commented Dr. Loretta M. Itri, Genta`s President, Pharmaceutical Development, and Chief Medical Officer. "Successful development of an oral taxane has been a research goal that has eluded many pharmaceutical companies. Tesetaxel has already been tested in more than 250 patients with various types of cancer in the U.S.,Europe, and Japan. By eliminating serious hypersensitivity infusion reactions, as well as potentially reducing nerve damage and overcoming resistance to standard taxanes, tesetaxel may offer important new treatment options for patients with advanced cancer."
"Having been associated with this drug since its original Phase 1 trial, I am
delighted to lead this key study that will enable the pivotal trials to
proceed," said Dr. Anthony Tolcher, Director of Clinical Research, South Texas
Accelerated Research Therapeutics, San Antonio, TX. "Completed Phase 2 studies of tesetaxel in advanced breast, colon and stomach cancer have shown promising activity. We believe the innovative development strategy created for tesetaxel may enable this drug to become the first oral taxane to achieve regulatory approval."
Genta Incorporated (OTCBB: GNTA) announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta's oncology product portfolio, has been granted designation as an "Orphan Drug" for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.
False
Genta has several products in the pipeline, including Tesetaxel. Go do some research, this isn't a one trick pony.
Genta is going to bull rush...
...right into the closing bell today. If anyone is really in this stock to make some serious cash, they'd be crazy to get out of their position prior to Monday and Tuesday....even all of next week. There is no telling what can come out of those meetings in terms of financing.
It's going to be great to hear right from the CEO's mouth what is going on with Genta and also some updates on the various trials that are being conducted.
It's pretty exciting and people have every reason in the world to buy this security up.
In my opinion, today is the best day to get in. If people are smart (granted, a lot aren't), they'll buy running into the close tomorrow. Monday and Tuesday morning are going to be very insightful and potentially extremely positive times for Genta.
Don' miss the boat.
I'll tell you why...
...because an oncologist who was on the FDA Oncology Boards opinion is very, very valid. There is no more validation of opinion needed.
An Oncologist on the FDA Oncology Drug Advisory Committees take on Genasense + Chemotherapy for the treatment of CLL and Genta's decision to file an appeal...
"On behalf of our patients, we applaud Genta for taking this action, and we urge CDER leadership to reverse the initial Office action", said Dr. Alexandra Levine, Chief Medical Officer at the City of Hope National Medical Center, Duarte, CA, and a hematologist and current member of FDA's Oncology Drug Advisory Committee (ODAC) who did not participate in ODAC's deliberations on Genasense. "It is puzzling that the Office would deny approval to a drug that met both its primary as well as a key secondary endpoint, especially since these findings were observed in the only randomized controlled trial that has ever been conducted in patients with relapsed CLL. These findings were statistically significant, and they represent clear benefit to patients."
I'd say more than "someone"...
...10's of thousands of people have bought in above 165. They want to see a profit...that's called establishing a base.
Genta's highs continue to get higher and the lows do as well.
With the anticancer drugs in their pipeline and on the market, it's really no surprise. Big investors are going to have some interest on Monday and Tuesday.
What an exciting time.
The volume and momentum are unstoppable...
...and it's not for no reason. This company has anticancer drugs on the market, orphan drug statuses, and groundbreaking drugs in the pipeline in late phase III trials.
People have to realize this stock was beaten down unfairly. It's on the naked short list (illegally shorted into the ground).
The train is not stopping folks.
This happens every morning...
...it's healthy and it's going to continue to help this stock (as it's done for months now). Repeat: These shake moves and headfakes and selloffs are healthy for GNTA.
Go get a cup of coffee.
Genasense® (oblimersen, Bcl-2 antisense): Researchers involved in a multicenter trial have reported that the addition of Genasense to Fludara® (fludarabine) and Cytoxan® (cyclophosphamide) improves the survival of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who achieve a complete remission (CR) or near complete remission (nCR).10
Genasense is a Bcl-2 antisense oligodeoxynucleotide that is being evaluated for the treatment of multiple myeloma, acute myeloid leukemia (AML), CLL, melanoma, and acute lymphoid leukemia (ALL). Bcl-2 is a potent inhibitor of apoptosis. Over-expression of this protein in patients with a variety of malignancies is associated with resistance to chemotherapy. Genasense down-regulates Bcl-2 and has been investigated in several hematologic malignancies where Bcl-2 has been implicated in disease resistance. In vitro studies suggest that Genasense can down-regulate Bcl-2 activity and inhibit cell viability.
Researchers from several institutions have previously reported the outcomes of 241 patients with advanced CLL treated with Fludara and Cytoxan with or without Genasense.11 The addition of Genasense increased the proportion of patients who achieve CR/nCR from 7% in the Fludara/Cytoxan only arm to 17% in the Genasense arm. Overall response rates were not different between the two groups. Maximum benefit was observed in Fludara-sensitive patients, who had a fourfold increase in the CR/nCR rate. Responses were more durable in the patients receiving Genasense. The estimated median survival in the Genasense group was 33.8 months compared with 32.9 months in the chemotherapy-only group. The estimated three-year survival rate was 46% for the Genasense group and 37.5% for the chemotherapy only group.
In the ASCO 2008 presentation, researchers reported a median duration of CR of 22 months in patients receiving Fludara and Cytoxan; the median has not been reached for patients receiving Genasense. The median survival time for patients in CR has not been reached in the Genasense group, but was reached at 46 months in the non-Genasense group. The researchers reported that 12 of the 20 patients achieving a CR were alive in the Genasense group versus three of eight patients receiving Fludara and Cyoxan without Genasense. Complete response was continuing in five of 12 in the Genasense group versus zero of three in the Fludara and Cytoxan group. It was concluded that the addition of Genasense to Fludara and Cytoxan increased the CR rate, CR duration, and survival of patients achieving CR. The authors also suggest that CR is a valuable endpoint in evaluating therapies for CLL.
http://professional.cancerconsultants.com/oncology_main_news.aspx?id=43144
- Fludara® = Owned by Bayer
Cytoxan = Owned by Bristol Myers Squibb
2 HIGHLY respectable companies, and more potential buyers to the drug Genasense, or the company as a whole.
DD Credit: YesterdayTrader
An Oncologist on the FDA Oncology Drug Advisory Committees take on Genasense + Chemotherapy for the treatment of CLL and Genta's decision to file an appeal...
"On behalf of our patients, we applaud Genta for taking this action, and we urge CDER leadership to reverse the initial Office action", said Dr. Alexandra Levine, Chief Medical Officer at the City of Hope National Medical Center, Duarte, CA, and a hematologist and current member of FDA's Oncology Drug Advisory Committee (ODAC) who did not participate in ODAC's deliberations on Genasense. "It is puzzling that the Office would deny approval to a drug that met both its primary as well as a key secondary endpoint, especially since these findings were observed in the only randomized controlled trial that has ever been conducted in patients with relapsed CLL. These findings were statistically significant, and they represent clear benefit to patients."
Genta is currently working with the FDA on two major projects, with respect to Genasense (there are certainly other applications in ongoing trials, as I listed in prior posts...other major Pharma's using Genta (oblimersen).
1) Genasense + Chemotherapy in the treatment of CLL: This was the last NDA that received a non-approvable in early December. The price didn't start it's collapse until 6 days AFTER the announcement of non-approvable was made. You figure that one out, I haven't. I believe it was shorted and panic selling began. The FDA said that for CLL, more data was needed and that the NDA wasn't approvable "in its current form". Genta leadership felt strongly that the drug showed both efficacy and safety and submitted the appeal a week or 2 later (after the price had fallen hard). They said that they were going to meet with FDA leadership to understand the key issues to get them squared away. That is ONE effort of Genasense.
Now the 2nd:
2) Genasense + Chemotherapy as a treatment of melanoma: This is the AGENDA trial, it's separate from CLL and treats a completely different form of cancer. This NDA has been submitted a few times and has been given a few different reasons for non-approval. A while back, it was "need more data". Most recently, it was that there may have been bias in the analysis that produced the results. Genta is tackling these problems by doing 2 things. 1) Conducting a very large scale, world-wide, double-blind, randomized, placebo driven study named Agenda. Not only are they doing this, but they are having an INDEPENDENT analyst group report the results of the trial using the FDA's specified and requested method. So far, the results of the Agenda trial are flat out undeniable. The FDA will now have a plethora of world-wide, completely unbiased data, and completely unbiased analytical results. The update from the Agenda Phase III trial released in January got a rise out of investors (you can look at the charts) because they were very, very positive. I've linked the interim results, released in January 2009, in an image below.
http://i121.photobucket.com/albums/o207/AHummell/gen.png?t=1233716531
There is an appeal in from Genta to the FDA on their non-approvable decision on Genasense + Chemotherapy for the treatment of CLL. There is a completely separate trial of Genasense and it's treatment of Melanoma, the Agenda Phase III trial, which is producing great results.
These 2 things, along with the recent patents and orphan drug status approvals, are what is driving this stock. The pipeline is innovative and solid. Pair that with the Genta CEO sitting on the panel of the 2009 BIO CEO & Investors Conference coming up on Monday and Tuesday and you can quickly start to see why we're seeing such great performance out of Genta.
If investors are there to finance and invest in a drug company with innovative products, boasting proven results, at a cheap price...well, there are few better Biotech companies at this time than Genta.
It could get very interesting next week. Monday and Tuesday will be great for investors to hear an update on the two applications mentioned above, as well as other groundbreaking drugs in the pipeline for Genta. Here's a link for the webcast.
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=GNTA&item_id=2079510
Major Pharma's Listing Genasense and are depending on it's approval to move forward with their drugs. This decision from the FDA is going to be under ENORMOUS pressure, not only from the oncology community, but these billion dollar drug companies that can easily give Genasense a little "push" to get this drug through. They have a lot riding on the approval.
More validation of Genesense shows up in a patent application dated 1-22-09 by Abbott Labs
0144]Bcl protein family member inhibitors include AT-101 ((-)gossypol), GENASENSE.RTM. (G3139 or oblimersen (Bcl-2-targeting antisense oglionucleotide)), IPI-194, IPI-565, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-- (((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobe- nzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)pip- erazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl- )propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&f=G&l=50&d=PG01&p=1&S1=oblimersen&OS=oblimersen&RS=oblimersen
More recognition filed by Smith-Kline Patent Application dated Jan 22, 2009 mentions GNTA's G3139 bcl-2 antisense oligonucleotide.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&p=1&f=G&l=50&d=PG01&S1=genta&OS=genta&RS=genta
0300]Agents used in proapoptotic regimens (e.g., bcl-2 antisense oligonucleotides) may also be used in the combination of the present invention. Members of the Bcl-2 family of proteins block apoptosis. Upregulation of bcl-2 has therefore been linked to chemoresistance. Studies have shown that the epidermal growth factor (EGF) stimulates anti-apoptotic members of the bcl-2 family (i.e., mcl-1). Therefore, strategies designed to downregulate the expression of bcl-2 in tumors have demonstrated clinical benefit and are now in Phase II/III trials, namely Genta's G3139 bcl-2 antisense oligonucleotide. Such proapoptotic strategies using the antisense oligonucleotide strategy for bcl-2 are discussed in Water J S et al. (2000), J. Clin. Oncol. 18: 1812-1823; and Kitada S et al. (1994), Antisense Res. Dev. 4: 71-79.
Notice Genesense(GNTA) gets some good recognition in this recent patent application Jan 15-2009. Look under the heading, Treatment For Cancer (0010). (couple of paragraphs down)
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22genta+inc%22&OS="genta+inc"&RS="genta+inc"
A Recent Patent assigned to Celgene mentions Oblimersen(Genesense) multiple times ...Here is one mention of the drug.
one embodiment of the invention, the second active agent is administered intravenously or subcutaneously and once or twice daily in an amount of from about 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg. The specific amount of the second active agent will depend on the specific agent used, the type of disease being treated or managed, the severity and stage of disease, and the amount(s) of immunomodulatory compounds of the invention and any optional additional active agents concurrently administered to the patient. In a particular embodiment, the second active agent is oblimersen (Genasense.RTM.), GM-CSF, G-CSF, EPO, taxotere, irinotecan, dacarbazine, transretinoic acid, topotecan, pentoxifylline, ciprofloxacin, dexamethasone, vincristine, doxorubicin, COX-2 inhibitor, IL2, IL8, IL18, IFN, Ara-C, vinorelbine, or a combination thereof.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=oblimersen&OS=oblimersen&RS=oblimersen
Over 20 Patent applications for Celgene 2008-2009 with
citations regarding oblimersen(GNTA). This is the sale of the century.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=celgene&FIELD1=&co1=AND&TERM2=oblimersen&FIELD2=&d=PG01
Jan 29th Genentech Patent application with a reference to oblimersen(GNTA)
0246]Also included in the definition of "chemotherapeutic agent" are: (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX.RTM.; tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON.RTM. (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE.RTM. (megestrol acetate), AROMASIN.RTM. (exemestane; Pfizer), formestanie, fadrozole, RIVISOR.RTM. (vorozole), FEMARA.RTM. (letrozole; Novartis), and ARIMIDEX.RTM. (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors such as MEK inhibitors (WO 2007/044515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, for example, PKC-alpha, Raf and H-Ras, such as oblimersen (GENASENSE.RTM., Genta Inc.); (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYME.RTM.) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN.RTM., LEUVECTIN.RTM., and VAXID.RTM.; PROLEUKIN.RTM. rIL-2; topoisomerase 1 inhibitors such as LURTOTECAN.RTM.; ABARELIX.RTM. rmRH; (ix) anti-angiogenic agents such as bevacizumab (AVASTIN.RTM., Genentech); and pharmaceutically acceptable salts, acids and derivatives of any of the above.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&p=1&f=G&l=50&d=PG01&S1=oblimersen&OS=oblimersen&RS=oblimersen
Ha, what bank doesn't have toxic assets right now? That's an absurd conclusion jump at best.
Here comes the next leg up...
108's going quick!
Shorts are sweating bullets!
They drove this thing into the ground and now their day of repentance is on them.
Here we go! Next leg up is going to be HUGE!
EXPLOSION! No looking back
Shorts are losing!
Momo is too strong!! GENTA THE BEAST!!
Chart is incredible...
WHAT A BEAST!
PENNY COMING!!
Shorters are fighting their..
a##es off to keep this down, but they've been trying since .0022, unsuccessfully.
GNTA will end above a penny today, well above. There is too much coming up for this company to close down now. Highs are higher, lows are higher, conference coming up, great agenda results...sky is the limit, literally.
Shorts are sweating bullets.
1 Left at 98...
...there is over 13MM in volume in 10 minutes, 99% of it buys hitting the ask price.
Good lord huge buying going off at the ask this morning.
Today is the last day we see subpenny's.
5 Deep at Ask of .0095
We are going to soar over a penny today. People are starting to get fired up about the BIO CEO & Investors Conference on Monday.
We'll be sure to link the webcast prior to the conference, it should be exciting!
He didn't say...
...that he does think that. He said that he doesn't think it's as high as the internet rumors are claiming. Then he said that we'll find out this coming Monday for sure.
Major Pharma's Listing Genasense and are depending on it's approval to move forward with their drugs. This decision from the FDA is going to be under ENORMOUS pressure, not only from the oncology community, but these billion dollar drug companies that can easily give Genasense a little "push" to get this drug through. They have a lot riding on the approval.
More validation of Genesense shows up in a patent application dated 1-22-09 by Abbott Labs
0144]Bcl protein family member inhibitors include AT-101 ((-)gossypol), GENASENSE.RTM. (G3139 or oblimersen (Bcl-2-targeting antisense oglionucleotide)), IPI-194, IPI-565, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-- (((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobe- nzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)pip- erazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl- )propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&f=G&l=50&d=PG01&p=1&S1=oblimersen&OS=oblimersen&RS=oblimersen
More recognition filed by Smith-Kline Patent Application dated Jan 22, 2009 mentions GNTA's G3139 bcl-2 antisense oligonucleotide.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&p=1&f=G&l=50&d=PG01&S1=genta&OS=genta&RS=genta
0300]Agents used in proapoptotic regimens (e.g., bcl-2 antisense oligonucleotides) may also be used in the combination of the present invention. Members of the Bcl-2 family of proteins block apoptosis. Upregulation of bcl-2 has therefore been linked to chemoresistance. Studies have shown that the epidermal growth factor (EGF) stimulates anti-apoptotic members of the bcl-2 family (i.e., mcl-1). Therefore, strategies designed to downregulate the expression of bcl-2 in tumors have demonstrated clinical benefit and are now in Phase II/III trials, namely Genta's G3139 bcl-2 antisense oligonucleotide. Such proapoptotic strategies using the antisense oligonucleotide strategy for bcl-2 are discussed in Water J S et al. (2000), J. Clin. Oncol. 18: 1812-1823; and Kitada S et al. (1994), Antisense Res. Dev. 4: 71-79.
Notice Genesense(GNTA) gets some good recognition in this recent patent application Jan 15-2009. Look under the heading, Treatment For Cancer (0010). (couple of paragraphs down)
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22genta+inc%22&OS="genta+inc"&RS="genta+inc"
A Recent Patent assigned to Celgene mentions Oblimersen(Genesense) multiple times ...Here is one mention of the drug.
one embodiment of the invention, the second active agent is administered intravenously or subcutaneously and once or twice daily in an amount of from about 1 to about 1000 mg, from about 5 to about 500 mg, from about 10 to about 350 mg, or from about 50 to about 200 mg. The specific amount of the second active agent will depend on the specific agent used, the type of disease being treated or managed, the severity and stage of disease, and the amount(s) of immunomodulatory compounds of the invention and any optional additional active agents concurrently administered to the patient. In a particular embodiment, the second active agent is oblimersen (Genasense.RTM.), GM-CSF, G-CSF, EPO, taxotere, irinotecan, dacarbazine, transretinoic acid, topotecan, pentoxifylline, ciprofloxacin, dexamethasone, vincristine, doxorubicin, COX-2 inhibitor, IL2, IL8, IL18, IFN, Ara-C, vinorelbine, or a combination thereof.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=oblimersen&OS=oblimersen&RS=oblimersen
Over 20 Patent applications for Celgene 2008-2009 with
citations regarding oblimersen(GNTA). This is the sale of the century.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=celgene&FIELD1=&co1=AND&TERM2=oblimersen&FIELD2=&d=PG01
Jan 29th Genentech Patent application with a reference to oblimersen(GNTA)
0246]Also included in the definition of "chemotherapeutic agent" are: (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX.RTM.; tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON.RTM. (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE.RTM. (megestrol acetate), AROMASIN.RTM. (exemestane; Pfizer), formestanie, fadrozole, RIVISOR.RTM. (vorozole), FEMARA.RTM. (letrozole; Novartis), and ARIMIDEX.RTM. (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors such as MEK inhibitors (WO 2007/044515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, for example, PKC-alpha, Raf and H-Ras, such as oblimersen (GENASENSE.RTM., Genta Inc.); (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYME.RTM.) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN.RTM., LEUVECTIN.RTM., and VAXID.RTM.; PROLEUKIN.RTM. rIL-2; topoisomerase 1 inhibitors such as LURTOTECAN.RTM.; ABARELIX.RTM. rmRH; (ix) anti-angiogenic agents such as bevacizumab (AVASTIN.RTM., Genentech); and pharmaceutically acceptable salts, acids and derivatives of any of the above.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&p=1&f=G&l=50&d=PG01&S1=oblimersen&OS=oblimersen&RS=oblimersen
Think about the other major pharmas...
...that have new NDA's with Genasense listed as a component in their submission.
You think these huge companies don't have a lot riding on the approval of Genasense? We're talking major, major dollars here.
Short term? Over a penny...
...long term, depending upon approval of Genasense? Seriously, no telling...anywhere from 25-40 cents? Maybe more? Very possible.
That's my best guess. Tons of potential at these prices and once it gets over and HOLDS a penny or more, lots of others will start to get involved. It's been trading great. Just look at the charts, the highs are higher and the lows are higher. Eventually this is going to stay over a penny and I think it will be this week.
No one wants to let go of their shares too cheap, and we're talking about multiple, multiple millions of shares traded. That right there tells you that the shareholders see the potential and aren't about to get robbed by selling their shares too cheap. Too cheap appears to be .0085 at this point.
I predict a penny will be the baseline support in a week. I've been in this stock since it fell last December, so I've seen the movement and the money come and go. I feel great about this security. You'll have fun here, trust me.
I predict Genta has a great day tomorrow...
...and runs well over a penny.
Love it, closed with a green hammer...
...tomorrow we'll continue and should continue for quite some time.
2 left, UBSS on the ask, Nite on Bid with 89
It's going to be hilarious when...
...no 6 Billion figure is even mentioned at that conference. This stock is going to explode.
What would happen...
...if any company just stopped doing what it did? It would fail.
Come on man, quit reaching and speculating.
If ANY company just stopped doing what it did to make money, it would fail.
What if one of the stocks in your portfolio just stopped operating? What do you think would happen?
This is really a stupid question.
Haha, agree!
That would be hilarious.